Show simple item record

dc.contributor.authorMeraldi, V
dc.contributor.authorAudran, R
dc.contributor.authorRomero, JF
dc.contributor.authorBrossard, V
dc.contributor.authorBauer, J
dc.contributor.authorLopez, JA
dc.contributor.authorCorradin, G
dc.date.accessioned2017-05-03T16:58:39Z
dc.date.available2017-05-03T16:58:39Z
dc.date.issued2003
dc.date.modified2009-12-21T06:45:35Z
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/S0264-410X(03)00093-8
dc.identifier.urihttp://hdl.handle.net/10072/27866
dc.description.abstractThe goal of this project was the evaluation of a novel immunomodulatory adjuvant for human use, OM-174, which is a soluble adjuvant derived from Escherichia coli lipid A. For this study, we used a synthetic peptide, known for its safety and reproducibility and the murine model of BALB/c mice. The long peptide (PbCS 242-310) used corresponds to the C-terminal region of the circumsporozoite protein (CSP) that is the major protein on the surface of Plasmodium sporozoites. Subcutaneous injections of PbCS 242-310 in combination with soluble adjuvant OM-174 induced long lasting peptide-specific antibody titres comparable to those obtained by immunization with incomplete Freund's adjuvant (IFA). The ex vivo evaluation of the CD8+ T cell response by IFN-? ELISPOT assay revealed that the injection of polypeptide with OM-174 adjuvant induced, compared to IFA, a similar and an eight-fold increased frequency of peptide-specific lymphocytes in the draining lymph-nodes and in the spleen, respectively. The CD8+ T-cells are specific for the sequence PbCS 245-253, a well-known H-2Kd-restricted CTL epitope, and are cytotoxic as shown in a chromium release assay. Immunization of BALB/c mice with this polypeptide in combination with adjuvant OM-174 conferred a protection after challenge with live Plasmodium berghei sporozoites. The strong antibody and CTL responses observed to a synthetic peptide in mice, the safety profile of the adjuvant and its extensive physico-chemical characterization suggest that OM-174 has a potential use in vaccine formulations for humans.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeUnited States of America
dc.relation.ispartofpagefrom2485
dc.relation.ispartofpageto2491
dc.relation.ispartofissue19-20
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume21
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchImmunology not elsewhere classified
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode30
dc.subject.fieldofresearchcode32
dc.subject.fieldofresearchcode320499
dc.titleOM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2003
gro.hasfulltextNo Full Text
gro.griffith.authorLopez Ramirez, Alejandro


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record